ALPEGA-GROUP
25.2.2021 16:02:09 CET | Business Wire | Press release
Alpega Group, a leading provider of end-to-end transportation and logistics management software, has positioned itself to meet logistics challenges with impressive results in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005665/en/
Alpega’s business units had an outstanding performance last year. On one hand, their freight exchanges’ customer acquisitions strongly grew by 20% compared to the previous year and existing clients had a higher renewal rate. On the other hand Alpega TMS added 83 new customers and had a tremendous increase in usage of their smart booking solution.
Alpega’s CEO, Todd DeLaughter, commented on these results: “I’m very excited with Alpega’s excellent performance proving the value of our solutions and the commitment of our employees to relentlessly serve our customers”
Critical developments in Alpega Group’s businesses have made their solutions ideal for the supply chain disruptions the transport industry now faces. The following is a recap of recent changes and events at Alpega, all of which promise to have a ripple effect in the coming year.
Supporting the Transportation Industry During COVID-19
An important player in the pharma sector chose Alpega TMS to ensure enhanced visibility and supply chain optimization. They were very satisfied with the agility of the Alpega team to rapidly implement the solution to cope with their logistics challenges, critical to fighting COVID19.
With initiatives like free access to its various solutions, such as Teleroute freight exchange, spot and smart booking, Alpega Group has shown solidarity with the transport industry and continues to aid in its recovery.
New Partnerships and solutions
Alpega’s partnership ecosystem powers their TMS solution. In 2020 Alpega established key partnerships with industry leaders such as Xeneta, project44, Shippeo and FourKites. In 2021 these partnerships will boost supply chain transparency for Alpega’s existing and future clients.
A payment guarantee solution for carriers was launched by Teleroute freight exchange, a unique service that allows carriers to be protected against non-payment.
New Leaders for New Growth
Alpega Group strengthened its management team and welcomed new senior leaders in 2020, including Gwyn Clay as Chief Product Officer and Jörg Heinen as VP of IT.
About Alpega Group
Alpega Group is a leading global logistics software company offering modular solutions that cover all transportation and logistics complexity needs. By bringing together the best solutions and market expertise, the Alpega Group has created the transportation industry’s only scalable end-to-end software suite.
Alpega TMS empowers transport professionals to manage the logistics and supply chain processes, it transforms global and local supply chains into collaborative ecosystems, bringing together all parties involved. Alpega TMS’s unique scalability and best-in-breed standalone solutions ensure shippers benefit from a system that evolves alongside their needs, regardless of the complexity of their logistics processes. Our freight procurement solution, TenderEasy, provides a world-class solution for sourcing transportation providers across air, land and sea. In terms of freight exchanges, 123cargo, Teleroute and Wtransnet are leading European marketplaces designed to match spot shipments and truck capacity.
These platforms and the data which flows through them, alongside our 30+ years’ experience in transportation lets us enable businesses to optimize their supply chain planning and execution while benefitting from lower costs and higher visibility. Alpega’s solutions combine to create added value for customers. Our community of 80,000 carriers and 200,000 members are electronically connected every day to successfully manage critical transport processes. Alpega is present in 80 countries worldwide and employs over 600 people with 31 different nationalities.
For more information, visit www.alpegagroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005665/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom